Business, energy, technology, markets and global industry news from Business News Today

Type 1 diabetes

PharmaDeviceNews Type 1 diabetes
Patient-derived pancreatic islet organoids and multi-omics research illustrate Greenstone Biosciences’ Breakthrough T1D-backed effort to study beta-cell vulnerability in type 1 diabetes. Representative image.
Pharma & Biotech

Can Greenstone’s patient-derived islet organoids reveal why some beta cells fail first in type 1 diabetes?

Greenstone Biosciences will build patient-derived islet organoids to study beta-cell vulnerability and identify potential type 1 diabetes drug targets.

Read More
Insulet’s Omnipod 5 launch in Spain expands access to tubeless automated insulin delivery, continuous glucose monitoring and connected diabetes technology. Representative image.
Medical Devices & Diagnostics

Insulet expands Omnipod 5 to Spain, raising the stakes in Europe’s insulin pump market

Read how Insulet’s Omnipod 5 Spain launch could reshape tubeless insulin delivery, reimbursement and connected diabetes care.

Read More
Representative image: Syntax Bio’s expanded Series A funding highlights growing investor interest in Cellgorithm-driven stem cell therapy for type 1 diabetes.
Pharma & Biotech

Syntax Bio funding boost puts pancreatic beta cell therapy closer to preclinical test

Find out how Syntax Bio’s expanded Series A could shape Cellgorithm-based beta cell therapy for type 1 diabetes.

Read More
Representative image: A pediatric diabetes specialist reviews glucose data during an infusion visit as Sanofi’s Tzield expands into newly diagnosed stage 3 type 1 diabetes care.
Pharma & Biotech

Why Sanofi’s Tzield expansion changes the treatment window for type 1 diabetes

Discover how Sanofi’s Tzield approval could reshape newly diagnosed pediatric type 1 diabetes care and why major clinical questions remain.

Read More
Representative image of a patient reviewing digital glucose data with a clinician, illustrating how Insulet’s Omnipod 6 and fully closed-loop insulin delivery research could reduce daily diabetes management burden.
Medical Devices & Diagnostics

Insulet’s next diabetes technology challenge is not control alone, it is usability at scale

Find out how Insulet’s Omnipod 6 and fully closed-loop data could reshape automated insulin delivery for diabetes care.

Read More
Representative image of a physician reviewing glucose trend data with a diabetes patient, reflecting Cirius Therapeutics’ CIR-0602K research and the growing search for new insulin-sensitizing therapies beyond GLP-1 drugs.
Pharma & Biotech

Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity

Cirius Therapeutics is pushing CIR-0602K into the ADA 2026 spotlight. Find out why insulin sensitivity may be diabetes’ next battleground.

Read More
Pharma & Biotech

How NewcelX Ltd. is pursuing durable islet graft survival in the race for a functional diabetes cure

How NewcelX Ltd. is advancing NCEL-101 toward a functional diabetes cure through durable islet graft survival and immune protection strategies.

Read More
Pharma & Biotech

Sanofi’s Tzield gains pediatric approval but can early intervention truly change T1D outcomes

FDA expands Tzield use to young children with type 1 diabetes. Discover what this means for early intervention and long-term outcomes.

Read More
Pharma & Biotech

What PolTREG-T1D reveals about the future of cell therapy in autoimmune diseases

PolTREG advances its TREG cell therapy for type 1 diabetes toward EU approval. Learn what this milestone means for autoimmune disease treatment.

Read More
Medtronic’s MiniMed Go cleared by FDA
Medical Devices & Diagnostics

Medtronic’s MiniMed Go cleared by FDA: Can smart MDI finally close the algorithm gap in diabetes care?

Medtronic’s MiniMed Go earns FDA clearance. Learn how it could reshape insulin injection therapy by combining smart pens, CGM insights, and dose algorithms.

Read More